Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products
Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the d...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical sciences 2023-09, Vol.112 (9), p.2332-2346 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2346 |
---|---|
container_issue | 9 |
container_start_page | 2332 |
container_title | Journal of pharmaceutical sciences |
container_volume | 112 |
creator | Blümel, Markus Liu, Jing de Jong, Isabella Weiser, Sarah Fast, Jonas Litowski, Jennifer Shuman, Melissa Mehta, Shyam B. Amery, Leanne Tan, David Cheng Thiam Jia, Feng Shekhawat, Dushyant Dagallier, Camille Emamzadeh, Mina Medina, Annette Santos, Camilla Gasser, Florian Urban, Christian |
description | Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators. |
doi_str_mv | 10.1016/j.xphs.2023.05.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2811941777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354923001909</els_id><sourcerecordid>2811941777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-660901d5ff4405838d3063ef6a2d8f275db2501a857267664ebfa0c031fe1adc3</originalsourceid><addsrcrecordid>eNp9kEGLFDEUhIMo7rj6BzxIjl66fUk6SQ94cQd1FxYUVs8hk7xohp7OmKTF-fdmmNHjnh7Uqyqoj5DXDHoGTL3b9X8OP0vPgYseZA_An5AVkxw6BUw_Jaum8E7IYX1FXpSyAwAFUj4nV0Iz1X56RfxmyRnnSu9mv5Saj_QGS6Vfs3U1OqRppnHuloL0odptnGI9Ujt7ukn7g63xojzUxUcsNKRMb2Ka0o_o7NRakl9cLS_Js2Cngq8u95p8__Tx2-a2u__y-W7z4b5zQqraKQVrYF6GMAwgRzF6AUpgUJb7MXAt_ZZLYHaUmiut1IDbYMGBYAGZ9U5ck7fn3kNOv5a2w-xjcThNdsa0FMNHxtYD01o3Kz9bXU6lZAzmkOPe5qNhYE50zc6c6JoTXQPSNJYt9ObSv2z36P9H_uFshvdnA7aVvyNmU1zE2aGPGV01PsXH-v8Cf3uL3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2811941777</pqid></control><display><type>article</type><title>Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products</title><source>Alma/SFX Local Collection</source><creator>Blümel, Markus ; Liu, Jing ; de Jong, Isabella ; Weiser, Sarah ; Fast, Jonas ; Litowski, Jennifer ; Shuman, Melissa ; Mehta, Shyam B. ; Amery, Leanne ; Tan, David Cheng Thiam ; Jia, Feng ; Shekhawat, Dushyant ; Dagallier, Camille ; Emamzadeh, Mina ; Medina, Annette ; Santos, Camilla ; Gasser, Florian ; Urban, Christian</creator><creatorcontrib>Blümel, Markus ; Liu, Jing ; de Jong, Isabella ; Weiser, Sarah ; Fast, Jonas ; Litowski, Jennifer ; Shuman, Melissa ; Mehta, Shyam B. ; Amery, Leanne ; Tan, David Cheng Thiam ; Jia, Feng ; Shekhawat, Dushyant ; Dagallier, Camille ; Emamzadeh, Mina ; Medina, Annette ; Santos, Camilla ; Gasser, Florian ; Urban, Christian</creatorcontrib><description>Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1016/j.xphs.2023.05.002</identifier><identifier>PMID: 37160227</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Analytical chemistry ; Polymeric drug delivery system(s) ; Protein delivery ; Regulatory science</subject><ispartof>Journal of pharmaceutical sciences, 2023-09, Vol.112 (9), p.2332-2346</ispartof><rights>2023 American Pharmacists Association</rights><rights>Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-660901d5ff4405838d3063ef6a2d8f275db2501a857267664ebfa0c031fe1adc3</citedby><cites>FETCH-LOGICAL-c356t-660901d5ff4405838d3063ef6a2d8f275db2501a857267664ebfa0c031fe1adc3</cites><orcidid>0000-0001-8535-9407 ; 0000-0001-7685-5871 ; 0000-0002-7899-678X ; 0000-0002-3518-0668 ; 0000-0002-6757-3570 ; 0000-0003-4210-5321 ; 0000-0002-2354-2465 ; 0000-0003-3236-3554 ; 0000-0003-0774-5155 ; 0000-0003-4339-8074 ; 0000-0003-0759-1424 ; 0000-0001-5576-0734 ; 0000-0002-3641-2424</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37160227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blümel, Markus</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>de Jong, Isabella</creatorcontrib><creatorcontrib>Weiser, Sarah</creatorcontrib><creatorcontrib>Fast, Jonas</creatorcontrib><creatorcontrib>Litowski, Jennifer</creatorcontrib><creatorcontrib>Shuman, Melissa</creatorcontrib><creatorcontrib>Mehta, Shyam B.</creatorcontrib><creatorcontrib>Amery, Leanne</creatorcontrib><creatorcontrib>Tan, David Cheng Thiam</creatorcontrib><creatorcontrib>Jia, Feng</creatorcontrib><creatorcontrib>Shekhawat, Dushyant</creatorcontrib><creatorcontrib>Dagallier, Camille</creatorcontrib><creatorcontrib>Emamzadeh, Mina</creatorcontrib><creatorcontrib>Medina, Annette</creatorcontrib><creatorcontrib>Santos, Camilla</creatorcontrib><creatorcontrib>Gasser, Florian</creatorcontrib><creatorcontrib>Urban, Christian</creatorcontrib><title>Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.</description><subject>Analytical chemistry</subject><subject>Polymeric drug delivery system(s)</subject><subject>Protein delivery</subject><subject>Regulatory science</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kEGLFDEUhIMo7rj6BzxIjl66fUk6SQ94cQd1FxYUVs8hk7xohp7OmKTF-fdmmNHjnh7Uqyqoj5DXDHoGTL3b9X8OP0vPgYseZA_An5AVkxw6BUw_Jaum8E7IYX1FXpSyAwAFUj4nV0Iz1X56RfxmyRnnSu9mv5Saj_QGS6Vfs3U1OqRppnHuloL0odptnGI9Ujt7ukn7g63xojzUxUcsNKRMb2Ka0o_o7NRakl9cLS_Js2Cngq8u95p8__Tx2-a2u__y-W7z4b5zQqraKQVrYF6GMAwgRzF6AUpgUJb7MXAt_ZZLYHaUmiut1IDbYMGBYAGZ9U5ck7fn3kNOv5a2w-xjcThNdsa0FMNHxtYD01o3Kz9bXU6lZAzmkOPe5qNhYE50zc6c6JoTXQPSNJYt9ObSv2z36P9H_uFshvdnA7aVvyNmU1zE2aGPGV01PsXH-v8Cf3uL3g</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Blümel, Markus</creator><creator>Liu, Jing</creator><creator>de Jong, Isabella</creator><creator>Weiser, Sarah</creator><creator>Fast, Jonas</creator><creator>Litowski, Jennifer</creator><creator>Shuman, Melissa</creator><creator>Mehta, Shyam B.</creator><creator>Amery, Leanne</creator><creator>Tan, David Cheng Thiam</creator><creator>Jia, Feng</creator><creator>Shekhawat, Dushyant</creator><creator>Dagallier, Camille</creator><creator>Emamzadeh, Mina</creator><creator>Medina, Annette</creator><creator>Santos, Camilla</creator><creator>Gasser, Florian</creator><creator>Urban, Christian</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8535-9407</orcidid><orcidid>https://orcid.org/0000-0001-7685-5871</orcidid><orcidid>https://orcid.org/0000-0002-7899-678X</orcidid><orcidid>https://orcid.org/0000-0002-3518-0668</orcidid><orcidid>https://orcid.org/0000-0002-6757-3570</orcidid><orcidid>https://orcid.org/0000-0003-4210-5321</orcidid><orcidid>https://orcid.org/0000-0002-2354-2465</orcidid><orcidid>https://orcid.org/0000-0003-3236-3554</orcidid><orcidid>https://orcid.org/0000-0003-0774-5155</orcidid><orcidid>https://orcid.org/0000-0003-4339-8074</orcidid><orcidid>https://orcid.org/0000-0003-0759-1424</orcidid><orcidid>https://orcid.org/0000-0001-5576-0734</orcidid><orcidid>https://orcid.org/0000-0002-3641-2424</orcidid></search><sort><creationdate>20230901</creationdate><title>Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products</title><author>Blümel, Markus ; Liu, Jing ; de Jong, Isabella ; Weiser, Sarah ; Fast, Jonas ; Litowski, Jennifer ; Shuman, Melissa ; Mehta, Shyam B. ; Amery, Leanne ; Tan, David Cheng Thiam ; Jia, Feng ; Shekhawat, Dushyant ; Dagallier, Camille ; Emamzadeh, Mina ; Medina, Annette ; Santos, Camilla ; Gasser, Florian ; Urban, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-660901d5ff4405838d3063ef6a2d8f275db2501a857267664ebfa0c031fe1adc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analytical chemistry</topic><topic>Polymeric drug delivery system(s)</topic><topic>Protein delivery</topic><topic>Regulatory science</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blümel, Markus</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>de Jong, Isabella</creatorcontrib><creatorcontrib>Weiser, Sarah</creatorcontrib><creatorcontrib>Fast, Jonas</creatorcontrib><creatorcontrib>Litowski, Jennifer</creatorcontrib><creatorcontrib>Shuman, Melissa</creatorcontrib><creatorcontrib>Mehta, Shyam B.</creatorcontrib><creatorcontrib>Amery, Leanne</creatorcontrib><creatorcontrib>Tan, David Cheng Thiam</creatorcontrib><creatorcontrib>Jia, Feng</creatorcontrib><creatorcontrib>Shekhawat, Dushyant</creatorcontrib><creatorcontrib>Dagallier, Camille</creatorcontrib><creatorcontrib>Emamzadeh, Mina</creatorcontrib><creatorcontrib>Medina, Annette</creatorcontrib><creatorcontrib>Santos, Camilla</creatorcontrib><creatorcontrib>Gasser, Florian</creatorcontrib><creatorcontrib>Urban, Christian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blümel, Markus</au><au>Liu, Jing</au><au>de Jong, Isabella</au><au>Weiser, Sarah</au><au>Fast, Jonas</au><au>Litowski, Jennifer</au><au>Shuman, Melissa</au><au>Mehta, Shyam B.</au><au>Amery, Leanne</au><au>Tan, David Cheng Thiam</au><au>Jia, Feng</au><au>Shekhawat, Dushyant</au><au>Dagallier, Camille</au><au>Emamzadeh, Mina</au><au>Medina, Annette</au><au>Santos, Camilla</au><au>Gasser, Florian</au><au>Urban, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>112</volume><issue>9</issue><spage>2332</spage><epage>2346</epage><pages>2332-2346</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37160227</pmid><doi>10.1016/j.xphs.2023.05.002</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-8535-9407</orcidid><orcidid>https://orcid.org/0000-0001-7685-5871</orcidid><orcidid>https://orcid.org/0000-0002-7899-678X</orcidid><orcidid>https://orcid.org/0000-0002-3518-0668</orcidid><orcidid>https://orcid.org/0000-0002-6757-3570</orcidid><orcidid>https://orcid.org/0000-0003-4210-5321</orcidid><orcidid>https://orcid.org/0000-0002-2354-2465</orcidid><orcidid>https://orcid.org/0000-0003-3236-3554</orcidid><orcidid>https://orcid.org/0000-0003-0774-5155</orcidid><orcidid>https://orcid.org/0000-0003-4339-8074</orcidid><orcidid>https://orcid.org/0000-0003-0759-1424</orcidid><orcidid>https://orcid.org/0000-0001-5576-0734</orcidid><orcidid>https://orcid.org/0000-0002-3641-2424</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3549 |
ispartof | Journal of pharmaceutical sciences, 2023-09, Vol.112 (9), p.2332-2346 |
issn | 0022-3549 1520-6017 |
language | eng |
recordid | cdi_proquest_miscellaneous_2811941777 |
source | Alma/SFX Local Collection |
subjects | Analytical chemistry Polymeric drug delivery system(s) Protein delivery Regulatory science |
title | Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A32%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Industry%20Best%20Practice%20on%20in-use%20Stability%20and%20Compatibility%20Studies%20for%20Biological%20Products&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Bl%C3%BCmel,%20Markus&rft.date=2023-09-01&rft.volume=112&rft.issue=9&rft.spage=2332&rft.epage=2346&rft.pages=2332-2346&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1016/j.xphs.2023.05.002&rft_dat=%3Cproquest_cross%3E2811941777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2811941777&rft_id=info:pmid/37160227&rft_els_id=S0022354923001909&rfr_iscdi=true |